GlassScriptPhysician profile
Kimberly C Phillips
NPI 1265552442
$2,345.63
in general payments reported to CMS, 2019-2025
18 companies · $1,647 in 2025
The $1,647 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.43 · 2022: $279 · 2023: $201 · 2024: $187 · 2025: $1,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,035.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $710.77 | 2024-2025 | |
| Janssen Biotech, INC. | $324.91 | 2021-2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $277.31 | 2022-2025 | Xifaxan, Relistor |
| Novo Nordisk INC | $196.77 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $165.35 | 2022-2025 | |
| Madrigal Pharmaceuticals | $137.71 | 2025 | Rezdiffra |
| Genzyme Corporation | $104.57 | 2025 | |
| Pfizer INC. | $99.58 | 2021-2025 | |
| Gilead Sciences, INC. | $89.06 | 2022 | |
| Medtronic, INC. | $44.29 | 2025 | Inceptiv |
| Regeneron Healthcare Solutions, INC. | $35.99 | 2025 | Dupixent |
| Braintree Laboratories, INC. | $31.19 | 2022-2025 | Suflave |
| Enterra Medical, INC. | $28.43 | 2023 | |
| Daiichi Sankyo INC. | $23.43 | 2022 | |
| Inspiremd LTD | $22.30 | 2025 | Cguard Prime Carotid Stent System |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $20.78 | 2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $18.66 | 2025 | Voquezna |
| Redhill Biopharma INC. | $14.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.